Ascidian and Lilly Sign $1.9B RNA Editing Kidney Pact

Ascidian and Lilly Sign $1.9 Billion RNA Editing Kidney Pact

The line between genetic medicine and RNA therapeutics continues to blur. Ascidian Therapeutics and Eli Lilly have entered into a research collaboration focused on RNA exon editing for genetic kidney diseases. The agreement gives Lilly the option to develop and commercialize therapies built on Ascidian’s platform, with total potential payments reaching $1.9 billion if all milestones are met.

The deal reflects a growing interest in RNA editing as an alternative to DNA-based gene therapies. While CRISPR and related tools have dominated headlines, RNA exon editing offers a different set of tradeoffs: it can correct splicing errors without altering the genome, potentially reducing off-target risks and enabling redosing. For diseases of the kidney, where many monogenic causes are known but few targeted treatments exist, the approach could open a new therapeutic avenue.

Collaboration Agreement

The pact between Ascidian Therapeutics and Eli Lilly is structured as a discovery and development partnership. Under its terms, Lilly gains the right to pursue RNA exon editing therapeutics for a defined set of genetic kidney diseases. Ascidian will lead initial discovery activities, while Lilly will handle later-stage development and commercialization. Financial details include an upfront payment (undisclosed), research funding, and up to $1.9 billion in potential milestone payments and royalties.

The collaboration is nonexclusive in certain areas, meaning Ascidian retains the ability to work on other indications. Both companies have declined to specify which genetic mutations or disease subtypes are covered, but the agreement targets conditions where the underlying pathology stems from exon-level defects in kidney-expressed genes.

This is not Ascidian’s first high-value partnership. The company, launched in 2021, previously struck a deal with Roche for RNA exon editing in neurological diseases. That agreement, worth up to $1.8 billion, validated the platform’s potential beyond ophthalmology (Ascidian’s initial focus) and set the stage for the Lilly deal. Together, the two partnerships suggest that major pharmaceutical players see RNA exon editing as a platform technology with broad applicability, not a one-off solution for a single disease.

RNA Exon Editing: A New Frontier

RNA exon editing differs from both gene editing and traditional antisense therapy. Instead of cutting DNA or merely blocking translation, it works at the RNA level to correct splicing errors. Many genetic diseases are caused by mutations that disrupt the normal inclusion or exclusion of exons during pre-mRNA splicing. RNA exon editing uses engineered RNA molecules to redirect the spliceosome, the cellular machinery that removes introns and joins exons, to skip a faulty exon or include a missing one.

Ascidian’s platform uses a proprietary class of molecules called “RNA exon editors” that are delivered via adeno-associated virus (AAV) vectors. These editors contain sequences that base-pair with the pre-mRNA target and recruit splicing factors to alter exon selection. The result is a corrected mRNA transcript that codes for a functional protein, even though the underlying DNA mutation remains unchanged.

The approach has several theoretical advantages over DNA editing. First, it is reversible: because the RNA is turned over by the cell, any unintended effects are transient. Second, redosing is possible if the initial treatment dose proves insufficient. Third, the editing occurs without creating double-strand breaks in DNA, reducing the risk of chromosomal rearrangements or off-target edits at homologous sites.

However, challenges remain. Delivery to specific tissues, especially the kidney, is a major hurdle. AAV vectors are efficient for liver and muscle but less so for renal cells. The immune response to AAV capsids can also limit redosing. And because RNA exon editing requires sustained expression of the editor, long-term safety data are still being collected.

Targeting Genetic Kidney Diseases

The partnership focuses on genetic kidney diseases, a category that includes hundreds of monogenic disorders. Common examples include polycystic kidney disease, Alport syndrome, Fabry disease, and cystinosis. Many of these conditions are progressive and lead to end-stage renal disease, requiring dialysis or transplantation. Despite advances in supportive care, few disease-modifying therapies exist.

Kidney tissue presents unique challenges for RNA therapy. The organ is highly vascularized, but its filtration barrier restricts the passage of large molecules from blood into urine. Podocytes, mesangial cells, and tubular epithelial cells each have different uptake properties. For RNA exon editing delivered via AAV, achieving therapeutic levels in the correct cell type without systemic toxicity remains a key question.

Researchers at Ascidian have published preclinical data showing that their RNA exon editors can be designed to target mutations in kidney-expressed genes. In a 2023 study in Nature Communications, the company demonstrated that a single intravascular dose of an AAV-delivered RNA exon editor restored normal splicing of a mutated COL4A5 gene in a mouse model of Alport syndrome. The treated animals showed reduced proteinuria and improved kidney function compared to controls.

Whether those results translate to humans will depend on optimizing delivery, dosing, and durability. The Lilly agreement suggests confidence that the platform can be engineered for renal applications, but the field is still early. No RNA exon editing therapy has yet been approved for any indication, and only a handful have entered clinical trials.

Scientific Context and Challenges

The broader RNA editing field has seen a surge in activity over the past five years. Companies such as Wave Life Sciences, ProQR Therapeutics, and Ribometrix have pursued RNA-based approaches for diseases ranging from cystic fibrosis to blindness. Meanwhile, CRISPR-based RNA editing platforms developed by companies like Locanabio and Korro Bio have attracted significant investment.

What distinguishes Ascidian from most competitors is its focus on exon editing rather than base editing. Base editors change individual nucleotides, whereas exon editors flip entire blocks of coding sequence. This allows the correction of larger mutations, including frameshifts and complex rearrangements, that cannot be fixed by single-nucleotide interventions. The tradeoff is that exon editing is less generalizable: it works only for diseases where a single exon can be skipped or included to restore function.

For genetic kidney diseases, that requirement often holds. Many mutations in collagen genes, for example, cluster in specific exons. Skipping a mutated exon can yield a shorter but still functional protein, a strategy analogous to exon skipping in Duchenne muscular dystrophy, where antisense oligonucleotides have been approved. The key difference is that RNA exon editing uses a permanent genetic payload (AAV-delivered editor) rather than repeated infusions of synthetic oligonucleotides.

Safety is the primary concern. AAV vectors integrate into the host genome at low frequencies, raising theoretical risks of insertional mutagenesis. The editors themselves could trigger off-target splicing changes if they bind to similar sequences in other transcripts. And because the editors are expressed from a viral vector, the immune system may clear transduced cells over time, reducing treatment durability.

Nevertheless, the potential reward is high. A one-time treatment that corrects a genetic kidney disease could eliminate the need for lifelong dialysis or multiple organ transplants. For patients with early-stage disease, it could preserve kidney function and prevent progression. With the cost of end-stage renal care exceeding $100,000 per patient per year in the United States, even modest reductions in disease burden could justify expensive therapies.

Frequently Asked Questions

Q: How does RNA exon editing differ from CRISPR-based gene editing?

A: RNA exon editing works on messenger RNA after it has been transcribed from DNA, whereas CRISPR edits the DNA itself. RNA editing is reversible, does not create double-strand breaks, and allows for redosing. However, the effects are not permanent because RNA is constantly degraded and resynthesized by the cell. For diseases where sustained protein expression is needed, RNA exon editing requires ongoing production of the editing molecule.

Q: Why is $1.9 billion considered a reasonable deal for a platform that has not yet produced a marketed drug?

A: The $1.9 billion figure includes all potential milestone payments for research, development, and commercial milestones across multiple programs. Only a fraction is paid upfront; the rest depends on achieving defined goals. For Lilly, the deal provides access to a novel technology with possible application to a large unmet need (genetic kidney disease). If successful, the platform could support multiple products, each with blockbuster potential.

Q: Are there any approved RNA exon editing therapies today?

A: No. No RNA exon editing therapy has received regulatory approval in any country. The field is in early clinical development. The most advanced programs are in ophthalmology and neurology, with the first human trials expected to report data in the next one to two years. The Lilly-Ascidian collaboration is focused on preclinical discovery, so human trials for kidney indications are likely several years away.